Yutaka Matsuura

Cogenics Icoria, Inc. provides medical research services. The firm offers genomics and proteomics-related research instruments, consumables, data, including databases, software & other research-oriented products. Icoria offers gene expression analysis and other related services. Its tissue informatics software performs tissue analysis for toxicology studies of early-stage drug candidates and other purposes. The firm also provides biomarkers to develop diagnostics and therapies for liver injuries, metabolic conditions & cancer. The company is headquartered in Research Triangle Park, NC.

Mitsui & Co. Global Strategic Studies Institute operates as an in-house research institute of Mitsui & Co. Ltd. It provides surveys and research in the fields of politics, economics, industry, society, technology, and innovation. The company was founded in October 1999 and is headquartered in Tokyo, Japan.

CarnaBio USA, Inc. provides biologicals and allied products. The company is headquartered in Natick, MA.

Part of Carna Biosciences, Inc., ProbeX, Inc. is a Japanese company that develops, manufactures, and distributes molecular imaging probe reagents. The company is based in Tokyo, Japan. ProbeX was acquired by Carna Biosciences, Inc. from Life Science Management, Inc. on October 01, 2013 for $2.82 million.

KinoPharma, Inc. manufactures pharmaceutical products. It deals with the research and development of protein phosphorylation enzyme and low molecular clinical drugs. The company was founded by Masatoshi Hagiwara on April 11, 2005 and is headquartered in Tokyo, Japan.

PharmaBio Corp. provides manufacturing and consulting company specializing in cellular and tissue based products. It offers of cell-based investigational new drugs, various contract testing and inspections including microbial safety testing of cells, specimen storage operations, development, manufacturing and marketing of clean room consumables and various equipment. The company was founded in April 1978 and is headquartered in Nagoya, Japan.

HuLA immune, Inc. is a Japanese company that provides immune cell therapy for cancer treatment. The company is based in Tokyo, Japan. The text in the company's description appears to be a mix of non-English languages, including British English and Japanese. It was founded in 2017 and the CEO is Yasuhiro Shindo.